Zealand Pharma — Juni 2024
-
Dansk aktie skiller sig ud som bedste investering inden for svær overvægt https://proinvestor.com/investornyt/1172938/dansk-aktie-skiller-sig-ud-som-bedste-investering-inden-for-svaer-overvaegt
-
JPMorgan Chase & Co.'s asset-management arm has amassed a $500 million-plus venture fund to capitalise on the soaring appetite for new weight-loss therapies, Bloomberg reported Thursday. The fund, dubbed 270 Life Sciences Private Capital Fund I, closed earlier this month and will place its biggest bets on therapies for obesity, according to Steve Squinto, chief investment officer of the bank's life sciences team. https://firstwordpharma.com/story/5866791
-
Mornings sharks
-
Novos ærkerival har sat fuld skub på udviklingen inden for svær overvægt https://proinvestor.com/investornyt/1172951/novos-aerkerival-har-sat-fuld-skub-pa-udviklingen-inden-for-svaer-overvaegt
-
Goddaw:)
-
har ikke selv adgang til adtiklen: https://medwatch.dk/Medicinal___Biotek/article17212325.ece?utm_source=Feed&utm_medium=latest
-
Godmorgen
-
For dem der evt måtte være interesseret, så er der en hulens masse solo snak fra mig i gubra chatten. Mest gubra men også lidt ZP og Viking
-
Hvorfor har kursudviklingen været så negativ gennem lang tid for Genmab? Og hvordan tegner det fremover? Zealand Pharma har haft en fantastisk kursudvikling, og nu står de over for nogle meget afgørende data. Data, der også vil påvirke Gubra, som ligeledes har amylin i pipelinen. Novo udvider produktionen i USA. Novonesis efterlader et positivt indtryk på investorerne efter kapitalmarkedsdagen forleden. https://proinvestor.com/boards/121002
-
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog Zealand Pharma announces positive topline results from the Phase 1b https://proinvestor.com/boards/121004
-
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial...
GlobeNewswire News Room (www.globenewswire.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind